Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/29/2025

Guideline Summary for Co‑administration of Cabozantinib and Ivermectin

Pharmacokinetic Interaction Potential

  • Neither cabozantinib nor ivermectin is a strong inhibitor or inducer of the other’s metabolic pathway (CYP3A4 or P‑gp), indicating minimal risk of clinically significant pharmacokinetic interaction. 3

Cabozantinib Monitoring and Adverse‑Effect Profile

  • Continuous monitoring of thyroid‑stimulating hormone (TSH) is recommended for patients receiving cabozantinib, especially those with prior total thyroidectomy, because TSH elevation occurs in approximately 57 % of such patients. 3
  • The most common adverse events with cabozantinib are diarrhea (grade ≥ 3 in ~15.9 % of patients), hand‑foot syndrome (~12.6 %), fatigue (~9.3 %), and hypertension; these figures are derived from phase III clinical trial data. 3
  • Dose reductions are frequently required, with 56 %–79 % of patients across clinical trials needing an initial dose reduction. This reflects moderate‑level evidence from multiple trial cohorts. 3

Ivermectin Administration Guidelines

  • Ivermectin should be taken with food to enhance oral bioavailability for parasitic infections. 1
  • The standard oral dose is 200 µg/kg; a single dose is used for cutaneous larva migrans, while a repeat dose after two weeks is recommended for scabies. 1
  • Caution is required in patients with hepatic impairment because ivermectin exposure can increase; this is especially pertinent when co‑administered with cabozantinib, which may cause hepatotoxicity. [1][2]

Practical Management of Concurrent Therapy

Pre‑prescribing Checks

  • Verify hepatic function (e.g., liver enzyme panel) before initiating ivermectin in a patient on cabozantinib, as severe liver disease may contraindicate ivermectin use. 2
  • Review the current cabozantinib dose and tolerability; if the patient has required dose reductions or is experiencing significant adverse events, consider scheduling ivermectin during a planned cabozantinib dose interruption when clinically feasible. 3

Overlapping Toxicities and Monitoring

  • Both agents can cause gastrointestinal symptoms; assess for overlapping toxicity and consider prophylactic antidiarrheal therapy. 3
  • Monitor for additive gastrointestinal toxicity—diarrhea occurs in >30 % of patients on cabozantinib and may be exacerbated by ivermectin. Prompt evaluation and supportive care (hydration, electrolyte monitoring) are advised. 3
  • Continue the established cabozantinib monitoring schedule (thyroid function, blood pressure, etc.) without alteration when ivermectin is added. 3

Safety Caveats

  • The lack of documented pharmacokinetic or pharmacodynamic interactions does not guarantee absolute safety; post‑marketing surveillance data for this specific combination are limited. 3
  • Ivermectin carries a risk of neurotoxicity in children weighing <15 kg and in patients with severe liver disease, independent of cabozantinib use. [1][2]
  • Cabozantinib formulations are not interchangeable: tablets (e.g., 60 mg daily for differentiated thyroid cancer) and capsules (e.g., 140 mg daily for medullary thyroid cancer) have different bioavailability profiles. 4

REFERENCES

2

Ivermectin Dosing Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3

Ivermectin Toxicity Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

Cabozantinib's Effects on Thyroid Profile [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025